FDA grants accelerated approval to Bristol's Zenbexus for multiple myeloma; PBMs adopt TrumpRx pricing; Novartis wins UK Entresto patent

The U.S. Food and Drug Administration granted accelerated approval to Bristol Myers Squibb's oral therapy Zenbexus for patients with advanced multiple myeloma. The drug represents a new class of treatment and is the first to be cleared using a more sensitive remission metric.

Pharmacy benefit managers have agreed to display price comparisons from the TrumpRx platform, a move aimed at increasing transparency of drug costs for prescribers and patients.

In the United Kingdom, Novartis secured a favorable ruling in a patent dispute over its heart‑failure medication Entresto, preserving its market exclusivity there.

These developments highlight ongoing regulatory progress, pricing transparency efforts, and intellectual‑property battles shaping the biotech landscape.